- This marks the fourth acquisition by CORONA Remedies from multinational corporations.
- Makes its entry into the Anti-Platelet monotherapy segment
- Increased its presence in the cardiology domain
- Leveraging its established equity with gynaecology and infertility specialists
NE BUSINESS BUREAU
AHMEDABAD, JULY 17
CORONA Remedies Limited on Thursday announced the acquisition of seven brands from the pharmaceutical division of Bayer in India.
Effective July 16, 2025, the acquisition encompasses several brands within the cardiology segment (NOKLOT) and the women’s healthcare portfolio (FOSTINE, LUPROFACT, MENODAC, OVIDAC, SPYE, and VAGESTON) for the Indian market. This strategic move strengthens CORONA Remedies position in both the cardiology and women’s healthcare segments. These products propose to offer growth under CORONA Remedies stewardship going forward.
Integrating these acquired brands into its portfolio marks CORONA Remedies entry into the Anti-Platelet Market, which is valued at Rs 1,507 Cr with an 8% growth rate¹. Furthermore, it aims to strengthen CORONA Remedies portfolio in women’s healthcare by enhancing its presence in the Gonadotrophin & Progesterone Hormone Market, which stands at Rs 1,862 crore as per MAT June’25. This portfolio is primarily utilized for infertility treatment and pregnancy management.
CORONA Remedies sales & marketing team and extensive distribution network will work to ensure that this newly acquired portfolio reaches patients across metro, semi-metro, urban, semi-urban, and rural areas.
The acquisition of these brands is expected to enhance CORONA Remedies market presence and expand its portfolio.
GCV Life acted as the advisor for this transaction.
